ReviewFrontiers in aging neuroscience2025
Drug discovery and development for Parkinson's disease: are preclinical models good enough?
Review in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- DYRK1A and Parkinson's disease, facts and hypotheses.Neurobiology of disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) remains a major challenge for translational neuroscience, with an increasing global prevalence and persistent unmet therapeutic needs. While its classical motor symptoms, such as bradykinesia, rigidity, and tremor, are well characterized, the clinical spectrum extends to diverse and often disabling non-motor manifestations, including hyposmia, constipation, and sleep disturbances. These features typically precede motor deficits and may dominate the late stages of disease. Despite decades of research, existing treatments remain primarily symptomatic and fail to halt disease progression. This situation has driven the development of a broad repertoire of preclinical models-ranging from
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.